Agency IQ

APRIL 12, 2024

Landscape analysis: A look at the regulation of decentralized trials and what’s coming soon In the past few years, regulators and researchers have shown increased interest in leveraging decentralized trial methods – especially following the pandemic. In early 2023, AgencyIQ conducted a landscape analysis of DCT policy in the U.S.

Regulations 40

Regulations Trials Science Clinical Trials 40

The Pharma Data

OCTOBER 27, 2021

GSK Consumer Healthcare today unveils a three-year programme to support the pharmacy profession with additional practical resources, mental health provisions and proposed policy changes as part of its new report Standing with Pharmacists in the Age of Self-Care.

Pharmacy 52

Pharmacy International Pharmaceuticals Regulations 52

Drug Discovery World

NOVEMBER 8, 2023

Global clinical regulations vary significantly, leading to disparities in medical treatment approvals. DDW Volume 24 – Issue 4, Fall 2023 References 2022 Heart Disease & Stroke Statistical Update Fact Sheet, American Heart Association. Without sufficient financial support, even the most promising trials may falter.

Clinical Trials 182

Clinical Trials Trials Disease Medical Schools 182

Drug Discovery World

NOVEMBER 29, 2022

St George’s, University of London’s Clinical Pharmacology course saw its first graduates this year and has already been named the third best pharmacy and pharmacology course in the UK by the Guardian and is currently the highest ranked pharmacology offering. Providing a broad view. Breaking down barriers.

Clinical Pharmacology 130

Clinical Pharmacology Clinical Trials Drugs Drug Development 130

FDA Law Blog: Biosimilars

MAY 13, 2024

Gibbs & Ana Loloei & Véronique Li, Senior Medical Device Regulation Expert — FDA has long touted the use of real-world evidence ( RWE ). RWD can be collected from a wide range of sources, such as electronic health records, registries, administrative claims, pharmacy data, and feedback from wearables and mobile technology.

FDA 111

FDA Production Trials Pharmacy 111

Drug Discovery World

FEBRUARY 22, 2023

Regulators, payers and other stakeholders (not to mention you and your team) will want to see that you have an infrastructure in place and are ready to go. DDW Volume 24 – Issue 1, Winter 2022/2023 About the author Craig Caceci, Managing Director, Terebellum.

Specialty Pharmacies 130

Specialty Pharmacies Drugs Marketing Clinical Trials 130

The Pharma Data

MAY 27, 2022

It is our goal to ensure that hospitals, specialty pharmacies, and retail store shelves will begin seeing adequate supplies again in the coming weeks.”. “We continue to work closely with our U.S. About 500,000 additional cans of specialized medical formula manufactured by Danone’s Nutricia business will be headed to the U.S.

FDA 52

FDA Specialty Pharmacies Pharmacy Production 52

Drug Discovery World

MARCH 29, 2023

What of the increased possibilities for ‘replacement pharmacy compounding’ for weekly hospital supplies, and for routine manufacturing of cell and gene therapies without a marketing authorisation? She also does not believe that the problems with Europe’s medicines can be solved with regulation.

Clinical Trials 130

Clinical Trials Biosimilars Pharma Companies Production 130

Agency IQ

SEPTEMBER 15, 2023

BY AMANDA CONTI SEP 13, 2023 1:58 PM CDT Quick background on nonprescription drug regulation Nonprescription drugs, also known as over-the-counter (OTC) drugs, are regulated differently than traditional prescription drugs. Overall, 2022 phenylephrine retail sales reached $1.8 billion, compared with retail sales of $0.5

Science 40

Science FDA Clinical Trials Pharmacy 40

Drug Discovery World

APRIL 14, 2023

as a master regulator of prostate differentiation and cancer initiation and progression, for generating unique and reliable murine bladder and prostate cancer models, and for steadfast commitment to serving as a leader, mentor, and supporter of women in cancer research. She is also an investigator with the Howard Hughes Medical Institute.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

Agency IQ

JANUARY 4, 2024

For regulators, there are two primary concerns associated with impurities – that they may cause a drug substance to degrade (thereby reducing its efficacy or safety) and that the impurities (or their effects on the drug substance) may be harmful to patients. Read AgencyIQ’s analysis of the ICH guideline here ].

FDA 40

FDA Production Laboratories FDA Approval 40

Agency IQ

JUNE 16, 2023

The 51 regulations that FDA is currently working on The FDA today unveiled its much-anticipated Spring 2023 Unified Agenda, a document outlining the regulations the agency plans to release in 2023 and beyond. The anticipated date of publication is June 2023, meaning we should see this regulation imminently.

Regulations 40

Regulations FDA Science Production 40

Agency IQ

OCTOBER 20, 2023

” Interchangeable products can be substituted for the reference product at the pharmacy level, without prescriber intervention, within state and local regulations. In September 2022, the FDA held a workshop focused on increasing the efficiency of biosimilar development programs.

Science 40

Science Biosimilars FDA Production 40

Agency IQ

JULY 12, 2024

Regulation (EU) 2022/123 , which called for a “reinforced role for EMA in crisis preparedness and management for medicinal products and medical devices,” expanded EMA’s mandate to monitor and mitigate shortages at the E.U. The sales data evaluated was from 2022, which. See AgencyIQ’s analysis of EMA’s milestones.]

Regulations 40

Regulations Packaging Production FDA 40

Agency IQ

JANUARY 26, 2024

Though regulations guide some aspects of how expiration dates are determined, the agency has but limited power to extend those dates unilaterally. As part of current good manufacturing practice (cGMP) regulations, drugs are required to bear an expiration date determined by “appropriate stability testing,” according to 21 CFR 211.137.

Science 40

Science FDA Packaging Production 40

Agency IQ

DECEMBER 1, 2023

What We Expect the FDA to do in December 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. The December calendar is packed with regulatory and industry meetings.

FDA 40

FDA Science Regulations Production 40

Agency IQ

SEPTEMBER 29, 2023

What We Expect the FDA to do in October 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Regulations Production 40

Agency IQ

OCTOBER 27, 2023

What We Expect the FDA to do in November 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. November is packed with regulatory and industry meetings.

FDA 40

FDA Science Regulations Production 40

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

Manufacturers must also ensure that all electronic FDA listings and all NDC listings with the electronic database vendors used to process pharmacy claims, including information about discontinued drugs, are up to date for all applicable drug and selected drug NDCs. had Part D expenditures on or before August 16, 2022).

Compliance 105

Compliance Pharmacy Drugs Licensing 105

FDA Law Blog: Biosimilars

JUNE 2, 2023

Kirschenbaum — Last Friday, May 26, CMS published in the Federal Register an assortment of proposals to change the regulations governing the Medicaid Drug Rebate Program. It is not our purpose to describe all of the nearly 20 changes proposed in this regulation, but the most noteworthy are described below, roughly in order of importance.

Drugs 59

Drugs Regulations Government Vaccine 59

Agency IQ

DECEMBER 11, 2023

Previously, burdensome side effects may have been written off as a necessary part of treatment and benefits measured in additional weeks or months of survival time; today, though, patients, clinicians, and regulators expect more. The Office continues work on a broad array of projects, though not all have been active OCE pursuits.

FDA 40

FDA Science Clinical Trials Trials 40

Agency IQ

FEBRUARY 15, 2024

Draft published December 2022. CDRH Final 12/29/2023; overdue FDA must issue final guidance no later than one year after the close of the public comment period for the draft guidance.

FDA 40

FDA Science Biosimilars Production 40

Agency IQ

AUGUST 25, 2023

Cannabis groups to Congress: FDA should regulate CBD as a dietary supplement U.S. legislators have asked for help to reimagine how the FDA should regulate cannabidiol (CBD) following the agency’s determination that it could not make use of its existing legislative or regulatory authorities to do so.

Regulations 40

Regulations FDA Science Production 40

Drug & Device Law

SEPTEMBER 14, 2023

One particularly long-standing and road-winding issue has been FDA’s authority to discourage, prevent, and discourage the promotion of off-label use of FDA-regulated medical products. As we have pointed out many times, FDA does not regulate the practice of medicine. at *29-30. We agree with that to a degree. at *23 (quoting Texas v.

FDA 59

FDA Doctors Regulations Pharmacy 59

Drug & Device Law

JULY 18, 2022

United States , 2022 WL 2295024, 142 S. 2370 (2022), vacated the convictions of a couple of alleged “pill mill” doctors under the Controlled Substances Act upon finding that the government’s proof in their criminal trial did not meet the standard required by 21 U.S.C. At the end of the term, the Supreme Court, in Ruan v.

Government 59

Government FDA Pharmacy Production 59

Drug & Device Law

DECEMBER 29, 2023

As a matter of science, the purported link was imaginary, as discussed at great length in one of the many excellent Zantac ( 2022+4 ) MDL opinions. Indeed, even the weird alternatives the plaintiff advocated, such as “point of sale” signs and DTC advertising (assuming these were Prop 65 remedies at all), were still FDA-regulated labeling.

Testimonials 105

Testimonials FDA Drugs Vaccine 105

Drug & Device Law

FEBRUARY 20, 2023

In at least the short term, a popular pain reliever would have to be removed from pharmacies. 3d , 2022 WL 6225596 (S.D. 7, 2022), which addressed the same question in the context of the admissibility of expert testimony. 2022 WL 6225661, at *5 (S.D. 4:20-CV-02256, 2022 WL 6225573, at *3 (S.D. Ethicon, Inc. ,

FDA 59

FDA FDA Approval Testimonials Vaccine 59

Drug & Device Law

JANUARY 4, 2024

2022) (same result as to other COVID-19 vaccine). Alabama State Board of Pharmacy , 61 F.4th April 13, 2022) (available here ). 2022) (quoting this publication). “The Okuley’s Pharmacy & Home Medical , N.E.3d 25, 2023); Goins v. Saint Elizabeth Medical Center , 640 F. 3d 745, 753 (E.D. 4th 137, 139 (D.C.

Vaccine 59

Vaccine FDA FDA Approval Pharmacy 59

Drug & Device Law

OCTOBER 25, 2023

We don’t remember what the legislation was about, but we do remember the consumer affairs guy regaling us with stories about how easy it was for state investigators to find all sorts of violations of consumer fraud regulations. Central Admixture Pharmacy Services, Inc. , That isn’t necessarily the result of anything nefarious.

FDA 59

FDA Packaging Production Regulations 59

Drug & Device Law

NOVEMBER 30, 2022

21, 2022), involves a claim by the plaintiffs that a woman developed triple negative breast cancer as a result of using an antiperspirant that she asserts contained benzene. . The assertion that benzene was in the antiperspirant rested on testing by Valisure, an analytical pharmacy. Valisure calls itself “the pharmacy that checks.”

Pharmacy 59

Pharmacy FDA Production Regulations 59

Drug & Device Law

OCTOBER 10, 2023

Each claim alleges that defendants’ failure to comply with FDA’s regulations is an unfair business practice and/or causes “consumer confusion.” Central Admixture Pharmacy Services, Inc., That’s the FDA’s job, not the court’s. Similarly, the court in Nexus Pharmaceuticals, Inc. 48 F4th 1040, 1049 (9 th Cir.

FDA Approval 59

FDA Approval FDA Pharmacy Regulations 59

Drug & Device Law

JUNE 29, 2022

LLC , 2022 Minn. May 24, 2022), is unusual. The plaintiff cried foul, claiming that the defendant had copied its product, violated Minnesota law regulating pharmaceutical compounding, and defrauded customers. The plaintiff groused that it was improbable that Minnesota would not regulate outsourcing facilities.

FDA Approval 98

FDA Approval Regulations Pharmacy FDA 98